Compare AbCellera Biologics Inc (ABCL) vs TeraWulf Inc (WULF) Price & Performance

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

TeraWulf (WULF) trades at $17.08, down 3.04% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $165M but a significant net loss of -$1.9B, reflecting a profit margin of -1,179.95%. Despite negative profitability metrics, all 14 analysts maintain Buy ratings with a $38 consensus price target, citing growth potential from AI infrastructure expansion including a major Anthropic lease.

The stock presents a high-risk, high-reward opportunity with strong Wall Street conviction despite fundamental challenges. Key catalysts include the AI pivot and capacity expansion, but investors face substantial execution risks, capital requirements, and ongoing losses that could pressure the stock near-term.